This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Nausea appears in the amylin-analogue literature as it does in the incretin literature, and the two are not additive in a simple way when the drugs are combined. The combination trials report tolerability separately for that reason.
Adding this to the thread rather than to the wiki, because I am not confident enough for the wiki.
The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.
Small methodological point on cagrisema phase 2 paper: repeating a measurement is cheap and resolves most of what is being argued about here at no cost to anyone.
Post #31 is right about the mechanism and I think understates the practical bit.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
The general answer and the answer for your case may diverge here.
On post #31 — agreed on the reasoning, with one qualification.
I would keep cagrisema phase 2 paper and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and merging them is why the last one went badly.
The practical version of cagrisema phase 2 paper is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
The phase 3 combination programme is where the clinically interesting numbers will come from. Phase 2 established that the combination does something; the size of it in a larger population is a separate question.
Building on post #37 rather than restating it.
The strongest argument against my own position on cagrisema phase 2 paper, stated as well as I can state it, since nobody else has yet.
Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.
Published human data on cagrilintide alone is thinner than on the combination, which is the reverse of what most people assume from how it is discussed here.
Post #40 is the version of this I will quote in future. One addition.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
If anyone has run this properly I would rather read that than my own guess.
Where I part company with post #42, and it is a narrow parting.
What I would tell a new member reading about cagrisema phase 2 paper for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
The arithmetic in post #44 is right; the assumption feeding it is the part to check.
Amylin analogues affect gastric emptying as well, so the mechanism overlaps the incretins in at least one place. That overlap is part of why the combination's tolerability profile is not simply the sum of the two.
One of those cases where knowing the mechanism does not help the decision.
Distinguishing three things in the cagrisema phase 2 paper discussion that keep getting used interchangeably: the observation, the proposed mechanism, and the recommendation that gets attached to both.
Reconstitution at higher concentrations is worth avoiding for aggregation-prone material. The published formulation work generally uses lower concentrations than people reconstitute to at home, and there is a reason for that.
None of the above is medical advice and I am not qualified to give any.
Everything in post #46 holds. The case it does not cover is the one I have.
The monoisotopic mass sits near 3749.9 Da, and the same caveat applies as everywhere else: a mass consistent with the proposed structure is a necessary condition and not a sufficient one.
I would call that likely rather than established.
Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.
Adding thanks rather than a view. I do not have a view worth the space.
Post #49 describes the usual case. This is about the unusual one.
Cagrisema phase 2 paper came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.
Stating my assumptions rather than smuggling them in.
Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.
On post #53 — agreed on the reasoning, with one qualification.
Worth distinguishing the combination product from the two components bought separately and mixed. Those are different pharmaceutical objects and nothing published about the first applies to the second.
Worth saying I have only my own numbers here, and n is small.
Picking up post #57: that is the part I would want checked first.
My position on cagrisema phase 2 paper is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.
Good question, well framed, and I would like to see it answered properly.
On storage: aggregation-prone peptides are the ones where repeated warming and cooling does the most damage, and where a solution that looks fine may already have changed. Visual inspection is a weaker test here than usual.
That is my reading. Someone else read the same page differently and was reasonable.